Replies to post #461045 on NorthWest Biotherapeutics Inc (NWBO)

[hope4patients]

Adam’s post has the stench of desperation attached to it. Here’s a post from his “source”:

https://newsroom.ucla.edu/releases/personalized-vaccine-increase-long-term-survival-glioblastoma

[hoffmann6383]

great post senti

thanks for sharing

[MI Dendream]

You are the woman, Senti!

This fraud has lost all credibility under his pseudonyms, so he was hoping newbies would bow to the swamp rat himself.

No one buys any of this garbage anymore. Unfortunately, the broader market hasn’t realized the snake that he is. We will need to fight the likes of him post-approval.

Well, maybe OIG will solve that problem for us.

[Bob_LobLaw]

I actually appreciate Adam F coming on here to try and stir up this controversy. Many new investors who might review this board may have been asking themselves this very question. “Hey this Adam F guy just posted what I feared as well.” Then BOOM countless responses with clear evidence that he is full of *^%#. This exercise will end up backfiring. I love it!

[flipper44]

The joint patent application for the combination would have, almost with 100% certainty, an underlying data sharing agreement amongst the joint inventors. It would also likely have potential licensing arrangements and priority worked out. Linda is not stupid.

[reachjo]

No need to back that truck up, you got him on the first pass. The tire tracks on his back says it all. Amazing work senti!

[highwayman4life]

Lol....NICE.

We must be getting close, even if you shine a smidgen of light, they "all" scurry.

[ATLnsider]

Thanks for re-posting all of those direct quotes directly from Dr. Liau and Dr. Nghiemphu.

You would think that would be the end of the FUD, but sadly, I know it will not.

[erik007tc]

Excellent, superb Senti! Right to the source, I remember that post like yesterday. Thank you as always.

[CrashOverride]

Thank you!

[snoopycomic]

Great response Senti.

[vator]

Bump.

[Mionaer1]

First-hand information. Thanks Senti.

[The Danish Dude]

Great info Senti! And dr. P. Leia Nghiemphu from UCLA corroborated that at the UCLA Brain Tumor Virtual Conference Mar 12, 2021, where she received the question

"Why is the name of the vaccine “ATL-DC vaccine” and not DCVax-L? Are both generic the same?"

and answered

"The vaccine names are different but it is the same vaccine."

As stated by Lykiri here

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162535567

[eagle8]

Thank you for (re)posting your conversation With LL and PLN

Especially for the newbies and ignorant but also for the people who don't want to know.

Best to you sentiment.

[biosectinvestor]

Thanks Senti!

Also, last night I posted this on Twitter.

1/ Re $NWBO and #DCVaxL aka "ATL-DC" in brief:#DrLindaLiau, principal investigator for a Phase 3 #DCVaxL trial recently gave a lecture covering the #DCVaxLComboTrial with #Keytruda.

— biosectinvestor (@biosectinvestor) April 20, 2022

I included this screen shot from Dr. Liau's March 31, 2022 presentation at University of Miami:



With the further explanation:

"In reference to the combination, the slide clearly states at the bottom of the boxed section, "Induction (DCVax) of T cell response + inhibition of PD-1/PD-L1 interactions (anti-PD-1) leads to TIM upregulation"."

The Danish Dude further added a link in another thread later, which is more official:

https://trp.cancer.gov/spores/abstracts/ucla_brain.htm#h03

Project 1: Active immunotherapy combined with checkpoint modulation for glioblastoma

Project Co-Leaders:
Robert M. Prins, PhD (Basic Co-Leader)
Linda M. Liau, MD, PhD, MBA (Clinical Co-Leader)

The overall goals of this research project are to investigate mechanisms of immune evasion following treatment with dendritic cell (DC) vaccines, and to develop rational combinations of immunotherapeutic strategies to overcome the immunosuppressive milieu of the brain tumor microenvironment. Our previous work strongly suggested that, in addition to inducing T-cell infiltration into brain tumors, DC vaccination may also create a pro-inflammatory environment within the tumor that induces the immigration of immunoregulatory antigen presenting cells (defined herein as iAPC) expressing high levels of PD-L1 and IL-10. These cells are phenotypically similar to the iAPC that dominantly attenuate the T-cell response to chronic viral infection, and may counteract the effective anti-tumor T-cell responses induced by DC vaccination within the tumor microenvironment via a mechanism involving PD-L1/PD-1. Furthermore, inhibition of iAPC using an anti-PD-1 mAb or a CNS-penetrant CSF-1R inhibitor (PLX-3397) in conjunction with tumor lysate-pulsed DC vaccination (DCVax-L), resulted in significantly prolonged survival in tumor-bearing animals with large, well-established intracranial (i.c.) gliomas. We therefore postulated that clinically relevant anti-tumor cellular immunity against GBM must have two components: 1) significant induction of tumor-specific tumor-infiltrating lymphocytes (TIL); and 2) blockade of iAPC function within the tumor microenvironment. Our hypothesis is that the local cellular interactions between iAPC and T lymphocytes within the tumor microenvironment will be a critical factor influencing the efficacy of immunotherapies in glioblastoma patients. A better understanding of the biology of these cells should provide insight into more effective ways to induce therapeutic anti-tumor immune responses for this deadly type of brain tumor.

The three Specific Aims of this project are:

Aim 1: To understand the mechanisms by which iAPCs limit glioma-specific anti-tumor immune responses induced by active immunotherapy

Aim 2: To evaluate the efficacy of combining tumor lysate-pulsed DC vaccination (to induce TILs into the tumor) with immune checkpoint inhibition (to block iAPC function) in pre-clinical models in vivo, and explore the use of novel PET tracers as an imaging biomarker of response.

Aim 3: To develop predictive immunological and imaging biomarkers of response in recurrent glioblastoma patients enrolled in a Phase II clinical trial of DCVax-L +/- Nivolumab.

Proposed schematic of how non-neoplastic cells can be effectively targeted to influence clinically relevant anti-tumor immunity and immunotherapy

The importance of PD-1/PD-L1 in iAPC-mediated immune suppression. Proposed schematic of how non-neoplastic cells can be effectively targeted to influence clinically relevant anti-tumor immunity and immunotherapy

Yup, you're right.

The combo trial with Keytruda and the text mentions DCVax-L

SPECIFICALLY

Game over mr. Feuerstein!https://t.co/Nh58M3BBLs pic.twitter.com/SdrJP88yBE

— 🇩🇰 The Danish Dude 🇬🇱 (@FlemmingBruce) April 20, 2022

[Doc logic]

sentiment_stocks,

You sunk his cruiser, destroyer and sub while the battleship has already been hit 3 times. Best wishes.

[CherryTree1]

I have a question for you Senti.
How do you know that this is really Adam Feuerstein?
This member ID: AdamFeuerstein_STAT was created back in February 2018.
It is not the member ID where Feuerstein sent the secret code to supposedly validate his identity and used extensively on this board several years back.
This is a different member ID so this could be anyone claiming to be Adam Feuerstein and those supposed email exchanges with his picture to Denise could just be bogus all made up, crafted to look real.
Just a little warning because your response assumes this is really he and it may not be.

[jammy32]

I don’t think you’re lying. Thanks for the information and rebuttal.